Stock Markets June 12, 2026 08:42 AM

HUTCHMED Shares Gain After Phase III Sovleplenib Data Presented at EHA

ESLIM-02 results show higher durable and overall response rates versus placebo; regulatory review in China already underway

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
HCM

HUTCHMED's stock moved higher in premarket trading after the company presented positive Phase III results for sovleplenib in warm antibody autoimmune hemolytic anemia at the European Hematology Association Congress. The ESLIM-02 trial met its primary endpoint, reporting a markedly greater durable response rate and improvements across several secondary endpoints versus placebo in a 90-patient study conducted in China. The China National Medical Products Administration has begun priority review of an NDA submitted in April and previously granted Breakthrough Therapy Designation in March.

HUTCHMED Shares Gain After Phase III Sovleplenib Data Presented at EHA
HCM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • ESLIM-02 met its primary endpoint: sovleplenib achieved a 66% durable response rate during weeks 5-24 versus 15% for placebo.
  • Secondary outcomes favored sovleplenib, including a 70% overall response rate versus 22% for placebo, reduced use of rescue therapy (16% vs 54%), and fewer red blood cell transfusions (11% vs 43%).
  • Regulatory actions in China include acceptance and priority review of an NDA in April and Breakthrough Therapy Designation granted in March; sectors impacted include biotechnology, pharmaceuticals, and equity markets.

HUTCHMED (NASDAQ:HCM) shares climbed 2.4% in premarket activity Friday after the firm unveiled positive Phase III findings for sovleplenib in warm antibody autoimmune hemolytic anemia during a presentation at the European Hematology Association (EHA) Congress.

The ESLIM-02 study achieved its primary endpoint, with sovleplenib producing a 66% durable response rate between weeks 5 and 24, compared with a 15% durable response rate for patients receiving placebo. The randomized, double-blind trial enrolled 90 patients in China who had relapsed or were refractory to at least one prior standard therapy for warm antibody autoimmune hemolytic anemia.

The data were presented Thursday at the EHA Congress in Stockholm, Sweden, and the presentation was selected for inclusion in the official EHA Press Program.

Beyond the primary endpoint, sovleplenib demonstrated a 70% overall response rate versus 22% for placebo in the trial population. The study also showed reductions in secondary measures of clinical burden: 16% of patients in the sovleplenib arm required rescue therapy compared with 54% of placebo patients, and red blood cell transfusions were needed in 11% of the sovleplenib group versus 43% among those on placebo.

Onset of response was faster with sovleplenib, with a median time to response of 3.1 weeks versus 6.3 weeks for placebo. For those who achieved an overall response, the median cumulative duration of response was 16.1 weeks with sovleplenib compared with 6.1 weeks for placebo.

Regulatory progress in China has been noted alongside the clinical results. A New Drug Application for sovleplenib intended for adults with warm antibody autoimmune hemolytic anemia who showed an insufficient response to at least one prior glucocorticoid treatment was accepted for review and granted priority review by the China National Medical Products Administration in April. The NMPA previously awarded sovleplenib Breakthrough Therapy Designation in March.

Safety data from ESLIM-02 showed that grade 3 or higher treatment-emergent adverse events occurred in 43% of patients receiving sovleplenib and in 59% of patients in the placebo arm. No treatment-related deaths or treatment discontinuations were reported in the sovleplenib group.


What this means

The ESLIM-02 results provide evidence that sovleplenib produced higher durable and overall response rates than placebo in the study population, while also reducing the need for rescue therapies and transfusions. The NMPA's acceptance and priority review of an NDA, together with the Breakthrough Therapy Designation, establish a parallel regulatory pathway in China while the company advances its clinical position.

Risks

  • The clinical results are drawn from a 90-patient study conducted in China, which limits the dataset to that specific trial population and geography; this may affect interpretation by biotechnology and pharmaceutical stakeholders.
  • Grade 3 or higher treatment-emergent adverse events were reported in 43% of patients receiving sovleplenib, representing a safety consideration for clinicians, payers, and investors.
  • Regulatory outcomes remain pending despite priority review and Breakthrough Therapy Designation; final regulatory decisions by the China National Medical Products Administration will determine market access and commercial impact.

More from Stock Markets

Pop Culture Group Shares Collapse After $8M Dilutive Offering Priced at $0.15 Jun 12, 2026 Capital Economics Flags IPO Wave as Potential Stress Test for Equity Markets Jun 12, 2026 Mistral AI in Talks to Secure Roughly €3 Billion at About a €20 Billion Valuation Jun 12, 2026 J.P. Morgan Picks Four European Energy Names for Growth and Cash Returns Jun 12, 2026 Insider moves on June 11, 2026: Healthcare and tech see notable buys while software and chips record heavy selling Jun 12, 2026